Uncovering Potential: AngioDynamics's Earnings Preview

AngioDynamics ANGO is preparing to release its quarterly earnings on Wednesday, 2025-04-02. Here's a brief overview of what investors should keep in mind before the announcement.

Analysts expect AngioDynamics to report an earnings per share (EPS) of $-0.11.

AngioDynamics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Earnings History Snapshot

In the previous earnings release, the company beat EPS by $0.07, leading to a 0.0% drop in the share price the following trading session.

Here's a look at AngioDynamics's past performance and the resulting price change:

Performance of AngioDynamics Shares

Shares of AngioDynamics were trading at $9.39 as of March 31. Over the last 52-week period, shares are up 51.97%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Analysts' Perspectives on AngioDynamics

Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on AngioDynamics.

A total of 1 analyst ratings have been received for AngioDynamics, with the consensus rating being Buy. The average one-year price target stands at $15.0, suggesting a potential 59.74% upside.

Analyzing Analyst Ratings Among Peers

The analysis below examines the analyst ratings and average 1-year price targets of NeuroPace, Semler Scientific and Delcath Systems, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.

• The consensus among analysts is an Outperform trajectory for NeuroPace, with an average 1-year price target of $18.0, indicating a potential 91.69% upside.
• Analysts currently favor an Buy trajectory for Semler Scientific, with an average 1-year price target of $71.0, suggesting a potential 656.12% upside.
• Analysts currently favor an Buy trajectory for Delcath Systems, with an average 1-year price target of $22.33, suggesting a potential 137.81% upside.

Snapshot: Peer Analysis

The peer analysis summary provides a snapshot of key metrics for NeuroPace, Semler Scientific and Delcath Systems, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

Key Takeaway:

AngioDynamics ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, AngioDynamics is at the bottom compared to its peers.

Get to Know AngioDynamics Better

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

AngioDynamics: Financial Performance Dissected

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Decline in Revenue: Over the 3 months period, AngioDynamics faced challenges, resulting in a decline of approximately -7.88% in revenue growth as of 30 November, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: AngioDynamics's net margin is impressive, surpassing industry averages. With a net margin of -14.74%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): AngioDynamics's ROE stands out, surpassing industry averages. With an impressive ROE of -5.6%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): AngioDynamics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.67% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: AngioDynamics's debt-to-equity ratio is below the industry average. With a ratio of 0.03, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

To track all earnings releases for AngioDynamics visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.